Drug class
Small-molecule therapy for Niemann-Pick disease type C; mechanism-based pharmacological class not established
Mechanism of action
The mechanism(s) by which arimoclomol exerts its clinical effects in patients with Niemann-Pick disease type C is unknown, according to the US prescribing information. Proposed heat-shock-protein/lysosomal effects should not be presented as established clinical mechanism.
General use cases
- In combination with miglustat for treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and paediatric patients aged 2 years and older under the US FDA Miplyffa indication
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
